Pfizer/Samsung Collaboration to Focus on PGx Strategies to Personalize Liver Cancer Treatments in Korea
July 21, 2010
Pfizer/Samsung Collaboration to Focus on PGx Strategies to Personalize Liver Cancer Treatments in Korea
Under the terms of the partnership, Samsung will provide samples from Korean patients. Pfizer, in turn, will conduct genomic profiling on the samples and analyze the data in order to link gene signatures to patient outcomes.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MedImmune Turns to NGS in Collaboration with Shanghai Chest Hospital to Study Lung Cancer
February 29, 2012 / Clinical Sequencing News - Pfizer Explores Gene Markers' Ability to Predict Axitinib Response in Kidney Cancer
September 28, 2011 / Pharmacogenomics Reporter - Tohoku U Spinoff Targeting Pharma Industry with SRM-MS Assays for ADMET Research
August 5, 2011 / ProteoMonitor - 10-Year Nuvera Study Yields Multi-Signature Test to Predict Chemotherapy Response
May 25, 2011 / Pharmacogenomics Reporter - Genome/Transcriptome Sequencing Project Promises PGx Strategy for Rare Cancers
August 18, 2010 / Pharmacogenomics Reporter